Acadia Pharmaceuticals receives CRL for sNDA for NUPLAZID to treat ADP
Acadia Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) on its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin).